Conference Day 1, May 22

8:00 am Check-In & Coffee

8:45 am Chair’s Opening Remarks

  • Saso Cemerski Executive Director, Head of ImmunoOncology Discovery US, AstraZeneca

Tricky Terrain: Tackling Solid Tumors with Cell Engagers to Address Unmet Need & Mitigate Toxicity

9:00 am Bench to Bedside: Tebentafusp, the Story of the First Approved TCR Therapeutic


  • A historical overview exploring the context of building a novel pipeline and platform
  • Developing and characterizing transformative medicines to address unmet needs in cancer

9:30 am Understanding Cell Recruitment to Solid Tumors to Localize Targeting & Enhance Immune Response


  • Localizing immune cell recruitment to minimize systemic toxicity
  • Amplify anti-tumor activity and triggering of cytotoxic factors while combating immune evasion
  • Explore induction of immunological memory towards tumor-specific antigens

10:00 am Novel Dual Targeting T Cell Engager With Selective Tumor Activity in Solid Tumors


  • Engineering strategy to increase the therapeutic index of T cell engager molecules
  • Improving tumor selectivity to avoid on-target off-tumor toxicity

10:30 am Speed Networking


The ideal opportunity to get face-to-face with many of the brightest minds working in the cell engager field and introduce yourself to the attendees that you would like to have more in-depth conversations with your peers.

Balancing on Toxicity Tightropes for Cell Engager Therapies

11:30 am How to Enhance Translatability of Immunotherapies in Preclinical Models?

  • Kader Thiam Senior Vice President Discovery, Preclinical Models, and Services, GenOway


  • Focus on BRGSF-HIS hCD34+ reconstituted mice featuring human lymphoid and myeloid compartments and syngeneic humanized mouse models
  • Characterization of the immune response in the mice
  • Assessment of efficacy and safety induced by cell engagers

12:00 pm Roundtable Discussion: Resistance Risks? Comparing Cell Engagers to Alternate Cancer Treatments Such as ADCs & Cell Therapies to Evaluate Potential Risks


  • Question the learnings from alternate therapeutic strategies such as how CAR T developers manage CRS
  • Balance how cell engagers can fit into the standard of care or following patient treatment with these therapies
  • Discuss future directions and the looming risk of resistance. Can we prevent it ever developing?

From Discovery to Manufacturing: End-to-End T Cell Engager Development

12:30 pm KeywayTM TCRm T-cell Engagers Discovery and Engineering: Fully Integrated Workflow from Target Idea to Development Candidate

  • Dongxing Zha CTO - TCR Discovery & Engineering , Alloy Therapeutics Founder & CEO, Keyway TCR Discovery, Alloy Therapeutics


  • TCRm antibody enable the targeting of intracellular proteins that have not been addressed by conventional cancer immunotherapies while avoiding the manufacturing and regulatory challenges of other TCR-based modalities
  • Keyway TCRm Discovery is the industry leading service to deliver fully functional and highly-specific lead TCRm T cell engagers by integrating high quality pMHC generation, best-in-class antibody discovery capabilities, comprehensive AI/ML enabled specificity screening, and therapeutically-tailored functional testing
  • Keyway TCRm Discovery is led by pioneering minds in the field of TCR-based therapies and the team has successfully executed many partner projects across a variety of targets and HLA alleles.

1:00 pm Lunch & Networking

Engineering Improved Delivery, Stability, Affinity & Avidity for Enhanced Efficacy

2:00 pm Engineering & Assembling Novel Formats to Fine-Tune Affinity & Avidity


  • Revolutionizing protein structure of BITEs to boost selectivity, ensuring binding to tumor cells while sidestepping any unwanted interactions with healthy tissue
  • Achieving a balance between affinity and risk of CRS
  • Building robust translational and bioanalytical strategies to safely and effectively treat more cancers

2:30 pm Quantitative Systems Pharmacology Modeling to Facilitate Translations Between Bench & Bedside: Forward & Back & Branching Out

  • Fei Hua PhD Vice President & Head of Mechanistic, Quantitative systems pharmacology Modeling & Simulation Services, Applied BioMath


  • Quantitative systems pharmacology (QSP) modeling integrates in vitro data, in vivo PK and PD data, mechanism of action of the drug and biological understanding of the disease. I will demonstrate in my talk how QSP modeling is a powerful tool for translation to clinical as well as back translation from clinical to bench.
  • For T cell engager first-in-human studies, we developed a QSP model that captures the CD3:drug:TAA cross-linking complex formation to support higher starting dose than an exposure-based MABEL approach. It has also been used to guide efficacious dose selection since bispecific molecules can have bell-shaped dose responses where a higher dose could lead to reduced efficacy.
  • In addition to translation, QSP modeling can also be used early in R&D to guide novel platform design and perform in silico proof-of-concept simulations.

3:00 pm Mitigate Toxicity by Engineering & Assembling Novel Formats to Mitigate Toxicity


  • Optimizing protein structure of BITEs to achieve increased selectivity of binding to tumor cells to minimize interactions with healthy tissue
  • Navigating reducing affinity to reduce risk of CRS and toxicity, compared to decreased potency and risk reducing efficacy
  • Explore the promise of tri- and multi-specific cell engagers for dual targeting

3:30 pm Afternoon Break

3:45 pm Achieving Strong Avidity & Durability


  • Utilizing the natural features of immunoglobulins to achieve strong binding
  • Looking into the overall developability strengths and weaknesses of IGM based modalities

4:15 pm Chair’s Closing Remarks

  • Saso Cemerski Executive Director, Head of ImmunoOncology Discovery US, AstraZeneca

4:20 pm Drinks Reception